Luis Chu

6.5k total citations
18 papers, 1.5k citations indexed

About

Luis Chu is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Hematology. According to data from OpenAlex, Luis Chu has authored 18 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Pulmonary and Respiratory Medicine, 8 papers in Oncology and 5 papers in Hematology. Recurrent topics in Luis Chu's work include Colorectal Cancer Treatments and Studies (5 papers), Multiple Myeloma Research and Treatments (4 papers) and Cancer Treatment and Pharmacology (4 papers). Luis Chu is often cited by papers focused on Colorectal Cancer Treatments and Studies (5 papers), Multiple Myeloma Research and Treatments (4 papers) and Cancer Treatment and Pharmacology (4 papers). Luis Chu collaborates with scholars based in United States, Canada and Ireland. Luis Chu's co-authors include Catherine A. Azar, Thomas E. Seay, Linda H. Colangelo, Nicholas J. Petrelli, Séamus O’Reilly, Norman Wolmark, Samia Lopa, Greg Yothers, Louis Fehrenbacher and Michael J. O’Connell and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Luis Chu

17 papers receiving 1.4k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Luis Chu United States 12 797 539 412 399 309 18 1.5k
Veronica Lonati Italy 22 1.3k 1.6× 656 1.2× 405 1.0× 296 0.7× 307 1.0× 42 1.8k
Felix Chu United States 12 632 0.8× 539 1.0× 238 0.6× 588 1.5× 251 0.8× 19 1.7k
Edgardo S. Santos United States 21 576 0.7× 524 1.0× 230 0.6× 384 1.0× 159 0.5× 101 1.2k
Jindřich Fínek Czechia 23 874 1.1× 607 1.1× 402 1.0× 368 0.9× 135 0.4× 161 1.5k
H. Curé France 22 1.2k 1.5× 327 0.6× 742 1.8× 183 0.5× 410 1.3× 82 2.0k
Thomas Makatsoris Greece 22 1.0k 1.3× 338 0.6× 198 0.5× 362 0.9× 135 0.4× 85 1.5k
G. Des Guetz France 20 1.2k 1.5× 481 0.9× 243 0.6× 302 0.8× 492 1.6× 72 1.6k
G. Peruzzotti Italy 20 1.3k 1.6× 368 0.7× 1.2k 3.0× 460 1.2× 428 1.4× 44 2.1k
Pei-Rong Ding China 20 1.2k 1.5× 271 0.5× 271 0.7× 195 0.5× 145 0.5× 45 1.6k
Lina Tang China 23 831 1.0× 645 1.2× 171 0.4× 446 1.1× 129 0.4× 73 1.6k

Countries citing papers authored by Luis Chu

Since Specialization
Citations

This map shows the geographic impact of Luis Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Luis Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Luis Chu more than expected).

Fields of papers citing papers by Luis Chu

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Luis Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Luis Chu. The network helps show where Luis Chu may publish in the future.

Co-authorship network of co-authors of Luis Chu

This figure shows the co-authorship network connecting the top 25 collaborators of Luis Chu. A scholar is included among the top collaborators of Luis Chu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Luis Chu. Luis Chu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Cobleigh, Melody, DA Yardley, Adam Brufsky, et al.. (2017). Abstract P5-08-08: Baseline (BL) characteristics, treatment (tx) patterns, and outcomes in patients with hormone receptor (HR)+ vs HR– HER2+ disease from the SystHERs registry. Cancer Research. 77(4_Supplement). P5–8. 1 indexed citations
2.
Berdeja, Jesús G., Todd M. Bauer, James Essell, et al.. (2015). Bendamustine, Bortezomib and Dexamethasone (BBD) As First-Line Treatment of Patients (Pts) with Multiple Myeloma (MM) Who Are Not Candidates for High Dose Chemotherapy. Clinical Lymphoma Myeloma & Leukemia. 15. e70–e71.
3.
Berdeja, Jesús G., Michael R. Savona, Luis Chu, et al.. (2013). Bendamustine, Bortezomib and Dexamethasone (BBD) As First-Line Treatment Of Patients (Pts) With Multiple Myeloma Who Are Not Candidates For High Dose Chemotherapy. Blood. 122(21). 3193–3193. 4 indexed citations
4.
5.
Scher, Howard I., Xiaoyu Jia, Kim Chi, et al.. (2011). Randomized, Open-Label Phase III Trial of Docetaxel Plus High-Dose Calcitriol Versus Docetaxel Plus Prednisone for Patients With Castration-Resistant Prostate Cancer. Journal of Clinical Oncology. 29(16). 2191–2198. 185 indexed citations
6.
Siziopikou, Kalliopi P., Melody Cobleigh, Stewart Anderson, et al.. (2011). Preliminary results of centralized HER2 testing in DCIS of the breast: NSABP B-43.. Journal of Clinical Oncology. 29(15_suppl). 588–588. 1 indexed citations
7.
Allegra, Carmen J., Greg Yothers, Michael J. O’Connell, et al.. (2010). Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08. Journal of Clinical Oncology. 29(1). 11–16. 410 indexed citations
8.
Bukowski, Ronald M., Walter M. Stadler, David F. McDermott, et al.. (2010). Safety and Efficacy of Sorafenib in Elderly Patients Treated in the North American Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program. Oncology. 78(5-6). 340–347. 33 indexed citations
9.
Stadler, Walter M., Robert A. Figlin, David F. McDermott, et al.. (2010). Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer. 116(5). 1272–1280. 193 indexed citations
10.
Scher, Howard I., Ronald de Wit, William R. Berry, et al.. (2010). Docetaxel (D) plus high-dose calcitriol versus D plus prednisone (P) for patients (Pts) with progressive castration-resistant prostate cancer (CRPC): Results from the phase III ASCENT2 trial.. Journal of Clinical Oncology. 28(15_suppl). 4509–4509. 20 indexed citations
11.
Allegra, Carmen J., Greg Yothers, Michael J. O’Connell, et al.. (2009). Initial Safety Report of NSABP C-08: A Randomized Phase III Study of Modified FOLFOX6 With or Without Bevacizumab for the Adjuvant Treatment of Patients With Stage II or III Colon Cancer. Journal of Clinical Oncology. 27(20). 3385–3390. 200 indexed citations
12.
Treon, Steven P., Jacob D. Soumerai, Andrew R. Branagan, et al.. (2008). Lenalidomide and Rituximab in Waldenstrom's Macroglobulinemia. Clinical Cancer Research. 15(1). 355–360. 89 indexed citations
13.
Drabkin, Harry A., Robert A. Figlin, Walter M. Stadler, et al.. (2007). The Advanced Renal Cell Carcinoma Sorafenib (ARCCS) expanded access trial: Safety and efficacy in patients (pts) with prior bevacizumab (BEV) treatment. Journal of Clinical Oncology. 25(18_suppl). 5041–5041. 19 indexed citations
14.
Fields, Anthony, David Rinaldi, Charles Henderson, et al.. (2005). An open-label multicenter phase II study of oral lapatinib (GW572016) as single agent, second-line therapy in patients with metastatic colorectal cancer. Journal of Clinical Oncology. 23(16_suppl). 3583–3583. 43 indexed citations
15.
Prosnitz, Leonard R., Luis Chu, Gloria Broadwater, et al.. (1998). Complications of axillary lymph node dissection for carcinoma of the breast. Cancer. 83(7). 1362–1368. 193 indexed citations
16.
Chu, Luis, Linda Sutton, B. Peterson, Kathleen A. Havlin, & EP Winer. (1996). Continuous infusion 5-fluorouracil as first-line therapy for metastatic breast cancer.. PubMed. 6(4). 211–6. 11 indexed citations
17.
Winer, Eric P., Luis Chu, & Darcy Spicer. (1995). Oral vinorelbine (Navelbine) in the treatment of advanced breast cancer.. PubMed. 22(2 Suppl 5). 72–8; discussion 78. 28 indexed citations
18.
Graham‐Pole, John, Hannelore Wass, Sheila M. Eyberg, Luis Chu, & Stephen Olejnik. (1989). Communicating with dying children and their siblings: A retrospective analysis. Death Studies. 13(5). 465–483. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Veronica Lonati Breakdown of academic impact, for papers by Felix Chu Breakdown of academic impact, for papers by Edgardo S. Santos Breakdown of academic impact, for papers by Jindřich Fínek Breakdown of academic impact, for papers by H. Curé Breakdown of academic impact, for papers by Thomas Makatsoris Breakdown of academic impact, for papers by G. Des Guetz Breakdown of academic impact, for papers by G. Peruzzotti Breakdown of academic impact, for papers by Pei-Rong Ding Breakdown of academic impact, for papers by Lina Tang
Rankless by CCL
2026